Milestone Pharmaceuticals’ (MIST) Buy Rating Reaffirmed at HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $25.00 price target on the stock.

Separately, Rodman & Renshaw initiated coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, August 22nd. They set a “buy” rating and a $9.00 price objective on the stock.

Milestone Pharmaceuticals Price Performance

NASDAQ:MIST opened at $1.45 on Monday. The firm’s fifty day moving average is $1.46 and its two-hundred day moving average is $1.53. The firm has a market cap of $77.23 million, a price-to-earnings ratio of -1.16 and a beta of 1.72. The company has a debt-to-equity ratio of 1.61, a quick ratio of 19.13 and a current ratio of 19.13. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $3.52.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Thursday, August 8th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Research analysts expect that Milestone Pharmaceuticals will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its position in Milestone Pharmaceuticals by 177.0% during the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,800 shares in the last quarter. Lion Point Capital LP raised its stake in shares of Milestone Pharmaceuticals by 1.7% during the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock worth $3,089,000 after buying an additional 40,000 shares during the period. Finally, Valeo Financial Advisors LLC lifted its position in shares of Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after buying an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.